Review





Similar Products

95
Miltenyi Biotec cd105 antibody, anti-human
Cd105 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human/custom%40130-117-808%4042727576
Average 95 stars, based on 1 article reviews
cd105 antibody, anti-human - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
Miltenyi Biotec hcd105 pe vio 615
Hcd105 Pe Vio 615, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human%2C+REAfinity/pmc13286653-42-0-3
Average 94 stars, based on 1 article reviews
hcd105 pe vio 615 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd105 fitc
(a) Immunofluorescence staining showing expression of Vimentin (green) and <t>CD105</t> (red) in DPSC and SHED compared with HaCaT epithelial controls. (b) STRO-1 (green) immunostaining in SHED. Nuclei were counterstained with DAPI (blue). Scale bar = 100μm (c) Representative flow cytometry analyses demonstrating expression of mesenchymal stem cell markers (CD73, CD90, CD105, HLA-ABC) and absence of hematopoietic markers (CD34, CD45). All experiments were perfomed at passage 5 (d) Growth curves comparing cumulative population doublings of DPSC and SHED derived from four independent donors across serial passages. SHED displayed enhanced proliferative capacity and reduced donor-to-donor variability.
Cd105 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human%2C+REAfinity/bio_rxiv__64898__2026__06__25__733625-69-8-9
Average 94 stars, based on 1 article reviews
cd105 fitc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd105
CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) <t>CD105.</t> The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ <t>CD105,</t> and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.
Cd105, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human/pmc13114382-55-0-6
Average 95 stars, based on 1 article reviews
cd105 - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

95
Miltenyi Biotec vioblue a
CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) <t>CD105.</t> The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ <t>CD105,</t> and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.
Vioblue A, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human/pmc13114382-55-2-6
Average 95 stars, based on 1 article reviews
vioblue a - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd105
CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) <t>CD105.</t> The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ <t>CD105,</t> and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.
Cd105, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/PE+Anti-Human+CD105+Antibody/pm41912977-51-21-22
Average 94 stars, based on 1 article reviews
cd105 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec apc anti human cd105 antibody
CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) <t>CD105.</t> The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ <t>CD105,</t> and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.
Apc Anti Human Cd105 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105+Antibody%2C+anti-human%2C+REAfinity/us12564607-324-82-86
Average 94 stars, based on 1 article reviews
apc anti human cd105 antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Elabscience Biotechnology cd105 antibody
Differentiation and characterization of EPCs and ECs. A Schema for differentiation of hESCs to EPCs and then to ECs according to a reported method. B Immunofluorescence staining of hESCs markers: TRA-1-60, NANOG, OCT4 and SOX2. C Phase contrast showing the morphology of EPCs. D Flow cytometry analysis of surface markers of EPCs. E Phase contrast showing the morphology of ECs. F , G Relative mRNA expression of endothelial transcripts (CD144, <t>CD105,</t> and KDR) and markers related to hESCs (OCT4, SOX2, NANOG) of hESCs and ECs. H Immunofluorescent micrographs of ECs showing the expression of CD31, vWF and VE-Cadherin (VE-CAD). I Flow cytometry analysis of surface markers of ECs. N = 3 per group. * p < 0.05, ** p < 0.01
Cd105 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/PE+Anti-Human+CD105+Antibody/pmc12955322-43-32-37
Average 94 stars, based on 1 article reviews
cd105 antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc anti human endoglin
( A ) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see for the full proteomics results). ( B ) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for <t>endoglin,</t> and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. ( C ) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. ( D ) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. ( E ) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). ( F ) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in . ( G, H ) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. ( G ) De novo filopodia formation. ( H ) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—source data 1. PDF file containing original blot for , indicating the relevant bands. Figure 4—source data 2. Original file for Coomassie blue gel displayed in . Figure 4—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 6. Original files for western blot analysis displayed in .
Anti Human Endoglin, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+cd105/CD105%2FEndoglin+Rabbit+mAb/pmc12803517-2-2-7
Average 94 stars, based on 1 article reviews
anti human endoglin - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

Image Search Results


(a) Immunofluorescence staining showing expression of Vimentin (green) and CD105 (red) in DPSC and SHED compared with HaCaT epithelial controls. (b) STRO-1 (green) immunostaining in SHED. Nuclei were counterstained with DAPI (blue). Scale bar = 100μm (c) Representative flow cytometry analyses demonstrating expression of mesenchymal stem cell markers (CD73, CD90, CD105, HLA-ABC) and absence of hematopoietic markers (CD34, CD45). All experiments were perfomed at passage 5 (d) Growth curves comparing cumulative population doublings of DPSC and SHED derived from four independent donors across serial passages. SHED displayed enhanced proliferative capacity and reduced donor-to-donor variability.

Journal: bioRxiv

Article Title: Human SHED-derived extracellular cues activate a specialized neuroprotective and regenerative program in developing retinal ganglion cells

doi: 10.64898/2026.06.25.733625

Figure Lengend Snippet: (a) Immunofluorescence staining showing expression of Vimentin (green) and CD105 (red) in DPSC and SHED compared with HaCaT epithelial controls. (b) STRO-1 (green) immunostaining in SHED. Nuclei were counterstained with DAPI (blue). Scale bar = 100μm (c) Representative flow cytometry analyses demonstrating expression of mesenchymal stem cell markers (CD73, CD90, CD105, HLA-ABC) and absence of hematopoietic markers (CD34, CD45). All experiments were perfomed at passage 5 (d) Growth curves comparing cumulative population doublings of DPSC and SHED derived from four independent donors across serial passages. SHED displayed enhanced proliferative capacity and reduced donor-to-donor variability.

Article Snippet: Antibodies against the following human antigens were used: CD105-FITC (Miltenyi Biotect, Bergisch Gladbach, Germany, cat# 130-112-327, 1:50), CD90-FITC (Miltenyi Biotec, cat# 130-114-901, 1:50), CD44-VioBlue (Miltenyi Biotec, cat# 130-113-906, 1:50), CD73-APC (Miltenyi Biotec, cat# 130-111-909, 1:50), MSC Phenotyping Cocktail-PE (CD34, CD14, CD19, CD45, Miltenyi Biotec cat# 130-125-285, dilution according to the manufacturer’s instructions).

Techniques: Immunofluorescence, Staining, Expressing, Immunostaining, Flow Cytometry, Derivative Assay

CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) CD105. The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ CD105, and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.

Journal: Cells

Article Title: Alterations in Circulating Progenitor Cell Composition in Rheumatoid Arthritis

doi: 10.3390/cells15080726

Figure Lengend Snippet: CD235a + and CD45 − CD31 − stromal cells circulating in peripheral blood. ( a ) CD45/CD31 dot plot showing populations 16, 17, 18, 19 and 20. ( b ) UMAP shows the size of each cluster, and ( c ) TriMAP shows the relative cluster location. CD45/CD31 plots highlighting the expression of ( d ) CD235a, ( e ) CD133, ( f ) CD34 and ( g ) CD105. The intensity scale indicates high expression of the marker in red. Frequency of ( h ) Pop 20, ( i ) Pop 17, and ( j ) Pop 18. Mann-Whitney test. Dot plots showing the expression of ( k ) CD34/CD133, ( l ) CD271/ CD105, and CD90 with ( m ) CD105, ( n ) CD271, and ( o ) PDPN in Pop 16 and Pop 19. Frequency of ( p ) Pop 16 and ( q ) Pop 19. t -test for Pop 16; Mann–Whitney test for Pop 19. All dot plots show mean and SD, n = 12 RA and 9 HC.

Article Snippet: CD105 , VioBlue-A , 130-099-666 , Miltenyi Biotec , 1/100 , V3.

Techniques: Expressing, Marker, MANN-WHITNEY

Differentiation and characterization of EPCs and ECs. A Schema for differentiation of hESCs to EPCs and then to ECs according to a reported method. B Immunofluorescence staining of hESCs markers: TRA-1-60, NANOG, OCT4 and SOX2. C Phase contrast showing the morphology of EPCs. D Flow cytometry analysis of surface markers of EPCs. E Phase contrast showing the morphology of ECs. F , G Relative mRNA expression of endothelial transcripts (CD144, CD105, and KDR) and markers related to hESCs (OCT4, SOX2, NANOG) of hESCs and ECs. H Immunofluorescent micrographs of ECs showing the expression of CD31, vWF and VE-Cadherin (VE-CAD). I Flow cytometry analysis of surface markers of ECs. N = 3 per group. * p < 0.05, ** p < 0.01

Journal: Stem Cell Research & Therapy

Article Title: Apoptotic vesicles from endothelial cells promote endothelial progenitor cell differentiation and angiogenesis via miR-30a-5p mediated activation of the EGFR/PI3K/AKT/VEGF pathway

doi: 10.1186/s13287-026-04912-x

Figure Lengend Snippet: Differentiation and characterization of EPCs and ECs. A Schema for differentiation of hESCs to EPCs and then to ECs according to a reported method. B Immunofluorescence staining of hESCs markers: TRA-1-60, NANOG, OCT4 and SOX2. C Phase contrast showing the morphology of EPCs. D Flow cytometry analysis of surface markers of EPCs. E Phase contrast showing the morphology of ECs. F , G Relative mRNA expression of endothelial transcripts (CD144, CD105, and KDR) and markers related to hESCs (OCT4, SOX2, NANOG) of hESCs and ECs. H Immunofluorescent micrographs of ECs showing the expression of CD31, vWF and VE-Cadherin (VE-CAD). I Flow cytometry analysis of surface markers of ECs. N = 3 per group. * p < 0.05, ** p < 0.01

Article Snippet: Endothelial serum-free medium (ESFM), Human plasma fibronectin, DMEM/F12, and PBS were purchased from Gibco, Matrigel were purchased from Corning, SOX2, OCT4, NANOG, TRA-1-60, vWF, VE-Cad antibody was purchased form Abcam, CD31, CD34, CD105 antibody were purchased form elabscience.

Techniques: Immunofluorescence, Staining, Flow Cytometry, Expressing

Apo-EVs promote the differentiation of EPCs into ECs in vitro. A Images of EPCs under an optical microscope after different treatments. B – D Relative mRNA expression of CD144, CD105 and KDR of EPCs after different treatments. E , F Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. G , H Tube formation of EPCs after different treatments. Scale bars: 200 μm. N = 3 per group. ns p > 0.05, ** p < 0.01, and **** p < 0.0001

Journal: Stem Cell Research & Therapy

Article Title: Apoptotic vesicles from endothelial cells promote endothelial progenitor cell differentiation and angiogenesis via miR-30a-5p mediated activation of the EGFR/PI3K/AKT/VEGF pathway

doi: 10.1186/s13287-026-04912-x

Figure Lengend Snippet: Apo-EVs promote the differentiation of EPCs into ECs in vitro. A Images of EPCs under an optical microscope after different treatments. B – D Relative mRNA expression of CD144, CD105 and KDR of EPCs after different treatments. E , F Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. G , H Tube formation of EPCs after different treatments. Scale bars: 200 μm. N = 3 per group. ns p > 0.05, ** p < 0.01, and **** p < 0.0001

Article Snippet: Endothelial serum-free medium (ESFM), Human plasma fibronectin, DMEM/F12, and PBS were purchased from Gibco, Matrigel were purchased from Corning, SOX2, OCT4, NANOG, TRA-1-60, vWF, VE-Cad antibody was purchased form Abcam, CD31, CD34, CD105 antibody were purchased form elabscience.

Techniques: In Vitro, Microscopy, Expressing, Flow Cytometry

Apo-EVs Promote the Differentiation of EPCs into ECs by Activating the EGFR/PI3K/AKT/VEGF Signaling Pathway. A Volcano plot illustrates the DEGs between EPCs treated with Apo-EVs and the untreated EPCs. B GO analysis of DEGs. C Heat map of DEGs in the GO analysis related to cell differentiation, migration, and angiogenesis. D , E GSEA analysis and KEGG pathway of DEGs. F Expression levels of β-actin, VEGF, AKT, p-AKT, PI3K, p-PI3K and EGFR protein in EPCs after different treatments. G – I Relative mRNA expression of CD144, CD105 and KDR of EPCs after different treatments. J – K Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. N = 3 per group. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

Journal: Stem Cell Research & Therapy

Article Title: Apoptotic vesicles from endothelial cells promote endothelial progenitor cell differentiation and angiogenesis via miR-30a-5p mediated activation of the EGFR/PI3K/AKT/VEGF pathway

doi: 10.1186/s13287-026-04912-x

Figure Lengend Snippet: Apo-EVs Promote the Differentiation of EPCs into ECs by Activating the EGFR/PI3K/AKT/VEGF Signaling Pathway. A Volcano plot illustrates the DEGs between EPCs treated with Apo-EVs and the untreated EPCs. B GO analysis of DEGs. C Heat map of DEGs in the GO analysis related to cell differentiation, migration, and angiogenesis. D , E GSEA analysis and KEGG pathway of DEGs. F Expression levels of β-actin, VEGF, AKT, p-AKT, PI3K, p-PI3K and EGFR protein in EPCs after different treatments. G – I Relative mRNA expression of CD144, CD105 and KDR of EPCs after different treatments. J – K Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. N = 3 per group. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001

Article Snippet: Endothelial serum-free medium (ESFM), Human plasma fibronectin, DMEM/F12, and PBS were purchased from Gibco, Matrigel were purchased from Corning, SOX2, OCT4, NANOG, TRA-1-60, vWF, VE-Cad antibody was purchased form Abcam, CD31, CD34, CD105 antibody were purchased form elabscience.

Techniques: Cell Differentiation, Migration, Expressing, Flow Cytometry

Apo-EVs promote the differentiation of EPCs via miR-30a-5p. A Top 20 miRNAs were detected in Apo-EVs, and after comparing with the 1042 miRNAs capable of targeting PML, 6 miRNAs were screened. B miR-30a-5p showed the highest expression level among the 6 screened miRNAs in Apo-EVs. C , D . Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. E , F Relative mRNA expression of CD144 and CD105 of EPCs after different treatments. G Expression levels of PML, β-actin, VEGF, AKT, p-AKT, PI3K, p-PI3K and EGFR protein in EPCs after different treatments. N = 3 per group. * p < 0.05, *** p < 0.001, and **** p < 0.0001

Journal: Stem Cell Research & Therapy

Article Title: Apoptotic vesicles from endothelial cells promote endothelial progenitor cell differentiation and angiogenesis via miR-30a-5p mediated activation of the EGFR/PI3K/AKT/VEGF pathway

doi: 10.1186/s13287-026-04912-x

Figure Lengend Snippet: Apo-EVs promote the differentiation of EPCs via miR-30a-5p. A Top 20 miRNAs were detected in Apo-EVs, and after comparing with the 1042 miRNAs capable of targeting PML, 6 miRNAs were screened. B miR-30a-5p showed the highest expression level among the 6 screened miRNAs in Apo-EVs. C , D . Percentage of cells co-expressing CD34 and CD105 measured by flow cytometry after different treatments. E , F Relative mRNA expression of CD144 and CD105 of EPCs after different treatments. G Expression levels of PML, β-actin, VEGF, AKT, p-AKT, PI3K, p-PI3K and EGFR protein in EPCs after different treatments. N = 3 per group. * p < 0.05, *** p < 0.001, and **** p < 0.0001

Article Snippet: Endothelial serum-free medium (ESFM), Human plasma fibronectin, DMEM/F12, and PBS were purchased from Gibco, Matrigel were purchased from Corning, SOX2, OCT4, NANOG, TRA-1-60, vWF, VE-Cad antibody was purchased form Abcam, CD31, CD34, CD105 antibody were purchased form elabscience.

Techniques: Expressing, Flow Cytometry

( A ) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see for the full proteomics results). ( B ) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for endoglin, and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. ( C ) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. ( D ) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. ( E ) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). ( F ) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in . ( G, H ) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. ( G ) De novo filopodia formation. ( H ) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—source data 1. PDF file containing original blot for , indicating the relevant bands. Figure 4—source data 2. Original file for Coomassie blue gel displayed in . Figure 4—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 6. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see for the full proteomics results). ( B ) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for endoglin, and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. ( C ) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. ( D ) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. ( E ) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). ( F ) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in . ( G, H ) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. ( G ) De novo filopodia formation. ( H ) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—source data 1. PDF file containing original blot for , indicating the relevant bands. Figure 4—source data 2. Original file for Coomassie blue gel displayed in . Figure 4—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 6. Original files for western blot analysis displayed in .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Purification, Staining, SDS Page, Western Blot, Control, Marker, Incubation, Knockdown, Transfection

( A ) Nanoparticle tracking analysis traces for B16F1 control (shScr) and endoglin-KD (shEng) SEVs. ( B ) SEV secretion rates from B16F1 shEng stable lines. N=5 biological replicates. ( C ) Representative western blot of Endoglin-KD in transient siRNA-transfected B16F1 cells. ( D ) Filopodia numbers in siRNA-transfected B16F1 cells (≥23 cells per condition per biological replicate, from three biological replicates). ( E ) Images from control and shHrs cells incubated with purified EV, corresponding to graph in . Scale bar in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Nanoparticle tracking analysis traces for B16F1 control (shScr) and endoglin-KD (shEng) SEVs. ( B ) SEV secretion rates from B16F1 shEng stable lines. N=5 biological replicates. ( C ) Representative western blot of Endoglin-KD in transient siRNA-transfected B16F1 cells. ( D ) Filopodia numbers in siRNA-transfected B16F1 cells (≥23 cells per condition per biological replicate, from three biological replicates). ( E ) Images from control and shHrs cells incubated with purified EV, corresponding to graph in . Scale bar in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Control, Western Blot, Transfection, Incubation, Purification

( A ) Western blot of Endoglin KD in HT1080 cells. ( B ) Nanoparticle tracking analysis traces of SEVs purified from shScr and shEng HT1080 cells showing size distribution (diameter) of SEVs and particles/mL/cell (N=3 biological replicates). ( C ) SEV secretion rates of HT1080 shScr and shEng HT1080 cells. ( D ) Representative images of HT1080 shScr and shEng cells. Images have been edited with brightness and contrast for ease of visibility. Scale bar in wide field and zoom insets = 10 mm. ( E ) Quantitation of filopodia density for control and shEng HT1080 cells.≥20 cells per condition per biological replicate, from four biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 2—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Western blot of Endoglin KD in HT1080 cells. ( B ) Nanoparticle tracking analysis traces of SEVs purified from shScr and shEng HT1080 cells showing size distribution (diameter) of SEVs and particles/mL/cell (N=3 biological replicates). ( C ) SEV secretion rates of HT1080 shScr and shEng HT1080 cells. ( D ) Representative images of HT1080 shScr and shEng cells. Images have been edited with brightness and contrast for ease of visibility. Scale bar in wide field and zoom insets = 10 mm. ( E ) Quantitation of filopodia density for control and shEng HT1080 cells.≥20 cells per condition per biological replicate, from four biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 2—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 2—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Western Blot, Purification, Quantitation Assay, Control

( A ) Western blot showing b1-integrin, TGFb1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. ( B ) Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9.≥20 cells per condition per biological replicate, from three biological replicates. ( C ) Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFb1.≥20 cells per condition per biological replicate, from three biological replicates. ( D ) Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). ≥20 cells per condition per biological replicate, from three biological replicates. ( E ) Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. ≥20 cells per condition per biological replicate, from biological replicates. Figure 6—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Western blot showing b1-integrin, TGFb1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. ( B ) Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9.≥20 cells per condition per biological replicate, from three biological replicates. ( C ) Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFb1.≥20 cells per condition per biological replicate, from three biological replicates. ( D ) Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). ≥20 cells per condition per biological replicate, from three biological replicates. ( E ) Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. ≥20 cells per condition per biological replicate, from biological replicates. Figure 6—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Western Blot, Control, Staining

( A ) Western blot analysis of total cell lysates (TCL) and SEVs from HT1080 control and shEng cells +/-rescue with WT endoglin or control expression vectors. The figure was made from cropped images of membranes to remove irrelevant lanes. ( B ) Quantification of endoglin expression (normalized to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. ( C ) Quantification of THSD7A expression (relative to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. ( D ) Quantification of filopodia in HT1080 control cells and shEng cells rescued with WT endoglin expression. N=3, at least 30 total cells per condition. ( E ) Representative confocal images of THSD7A-mScarlet-expressing control and shEng HT1080 cells immunostained for CD63. Box 1 shows extracellular THSD7A and CD63 deposits. Box 2 shows intracellular CD63-positive MVEs. For both boxes, the zoomed images have been adjusted for brightness and contrast (to equivalent levels for control and shEng cells) for easy visualization. Note that the overlap of THSD7A (magenta) and CD63 (green) gives a white signal, pointed out with white arrowheads in the shEng merged image in Zoom 2. Scale bar is 10 mm in wider field view and 5 mm in zoom insets. ( F ) Quantification of colocalization of internal CD63 and mScarlet signals in HT1080 cells from nonadjusted images.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 7—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 7—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Western blot analysis of total cell lysates (TCL) and SEVs from HT1080 control and shEng cells +/-rescue with WT endoglin or control expression vectors. The figure was made from cropped images of membranes to remove irrelevant lanes. ( B ) Quantification of endoglin expression (normalized to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. ( C ) Quantification of THSD7A expression (relative to flotillin-1 as a loading control, and relative to shScr control) from triplicate Western blots as in A. ( D ) Quantification of filopodia in HT1080 control cells and shEng cells rescued with WT endoglin expression. N=3, at least 30 total cells per condition. ( E ) Representative confocal images of THSD7A-mScarlet-expressing control and shEng HT1080 cells immunostained for CD63. Box 1 shows extracellular THSD7A and CD63 deposits. Box 2 shows intracellular CD63-positive MVEs. For both boxes, the zoomed images have been adjusted for brightness and contrast (to equivalent levels for control and shEng cells) for easy visualization. Note that the overlap of THSD7A (magenta) and CD63 (green) gives a white signal, pointed out with white arrowheads in the shEng merged image in Zoom 2. Scale bar is 10 mm in wider field view and 5 mm in zoom insets. ( F ) Quantification of colocalization of internal CD63 and mScarlet signals in HT1080 cells from nonadjusted images.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 7—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 7—source data 2. Original files for western blot analysis displayed in .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Western Blot, Control, Expressing

Control and endoglin-KD HT1080 cells were plated on coverslips coated with poly-D-lysine (PDL) or THSD7A. In some cases, cells were treated with the Cdc42 inhibitor ML141 (10 µM) or transfected with the dominant active Cdc42 mutant Q61L, as indicated.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: Control and endoglin-KD HT1080 cells were plated on coverslips coated with poly-D-lysine (PDL) or THSD7A. In some cases, cells were treated with the Cdc42 inhibitor ML141 (10 µM) or transfected with the dominant active Cdc42 mutant Q61L, as indicated.≥20 cells per condition per biological replicate, from three biological replicates. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Control, Transfection, Mutagenesis

( A ) In tumor cells, endoglin and THSD7A are trafficked into intralumenal vesicles (ILV) in multivesicular endosomes (MVEs) for secretion. Inhibiting the exosome biogenesis pathway by blocking Hrs or inhibiting MVE docking by blocking Rab27a subsequently reduces exosome secretion and filopodia formation. SEVs carrying THSD7A can induce filopodia on target cells via Cdc42, leading to increased cell motility and metastasis. When endoglin levels are lowered (such as by KD), THSD7A is retained inside cells in CD63-positive endosomes, and its levels in SEVs are greatly decreased. The drop in THSD7A levels in endoglin-KD EVs could be due either to a lack of trafficking into ILVs or, alternatively, enhanced lysosomal degradation of THSD7A-containing MVEs. Given that THSD7A accumulates in CD63-positive endolysosomal compartments in endoglin-KD cells , the latter possibility seems more likely. The cartoon was created using BioRender.com . ( B ) In primary neurons, exosome biogenesis is controlled by the formation of ILVs by Hrs and MVE docking is controlled by Rab27b. Knockdown of either of these proteins results in reduced formation of filopodia, dendritic spines, and synapses in both cortical and hippocampal neurons. Similar to cancer cells, THSD7A is carried in neuronal SEVs and induces filopodia. The cartoon was created using BioRender.com .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) In tumor cells, endoglin and THSD7A are trafficked into intralumenal vesicles (ILV) in multivesicular endosomes (MVEs) for secretion. Inhibiting the exosome biogenesis pathway by blocking Hrs or inhibiting MVE docking by blocking Rab27a subsequently reduces exosome secretion and filopodia formation. SEVs carrying THSD7A can induce filopodia on target cells via Cdc42, leading to increased cell motility and metastasis. When endoglin levels are lowered (such as by KD), THSD7A is retained inside cells in CD63-positive endosomes, and its levels in SEVs are greatly decreased. The drop in THSD7A levels in endoglin-KD EVs could be due either to a lack of trafficking into ILVs or, alternatively, enhanced lysosomal degradation of THSD7A-containing MVEs. Given that THSD7A accumulates in CD63-positive endolysosomal compartments in endoglin-KD cells , the latter possibility seems more likely. The cartoon was created using BioRender.com . ( B ) In primary neurons, exosome biogenesis is controlled by the formation of ILVs by Hrs and MVE docking is controlled by Rab27b. Knockdown of either of these proteins results in reduced formation of filopodia, dendritic spines, and synapses in both cortical and hippocampal neurons. Similar to cancer cells, THSD7A is carried in neuronal SEVs and induces filopodia. The cartoon was created using BioRender.com .

Article Snippet: Antibody , anti-human Endoglin (Rabbit monoclonal) , Cell Signaling , 4335 , WB 1:1000.

Techniques: Blocking Assay, Knockdown